Orexo and Abera Collaboration Overview
Orexo is embarking on an exciting collaboration with Abera Bioscience to leverage its innovative AmorphOX technology for developing nasal powder vaccines. This partnership aims to broaden the application of Orexo's powder-based drug delivery system, driving forward the potential of mucosal vaccine delivery.
About the AmorphOX Technology
The AmorphOX platform, developed by Orexo, represents a significant advancement in the field of drug delivery. This proprietary technology allows for the creation of powder formulations that improve the stability and efficacy of various active ingredients, including vaccines. By converting liquid formulations into a stable powder form, significant advantages in storage and transportation are achieved, ultimately enhancing patient accessibility to critical treatments.
Abera's Expertise in Vaccine Development
Abera has established itself as a leader in mucosal vaccine development, with a focus on creating innovative vaccines intended for delivery via nasal spray. With over three decades of research experience, Abera is well-equipped to innovate and enhance vaccine formulations, making them faster and more cost-effective to produce. The integration of AmorphOX technology is expected to complement Abera's existing platform and further improve the performance of their vaccine candidates.
Initial Focus on Influenza Vaccine Candidates
The collaboration will initially target the development of powder-based intranasal vaccines, particularly focusing on an influenza vaccine candidate from Abera. Influenza remains a significant public health concern, and the ability to deliver vaccines effectively through nasal routes presents an opportunity to reduce infection spread and enhance responsiveness during potential pandemics.
Expert Insights from Leadership
Maria Alriksson, CEO of Abera Bioscience, expressed enthusiasm about the partnership, stating, "The combination of Orexo’s advanced technologies and our in-depth knowledge of vaccine development promises a unique approach to tackle influenza and potentially other health challenges." Robert Rönn, SVP and Head of R&D at Orexo, added, "We are eager to explore the synergies between our technologies, which will pave the way for cutting-edge innovations in vaccine delivery."
Funding Through Grants
The innovative work between Orexo and Abera is facilitated by funding from various grants received by Abera, primarily from organizations dedicated to advancing medical preparedness. This financial support underscores the importance of the collaboration in addressing critical healthcare needs.
Orexo's Commitment to Healthcare Innovation
With over 30 years of experience, Orexo firmly believes in meeting substantial medical needs through its proprietary formulation technologies. The company actively works on solutions for patients dealing with opioid use disorder and continuously strives to innovate in various therapeutic areas, ensuring accessibility and efficacy in medication delivery.
About the Companies Involved
Orexo, a Swedish pharmaceutical company, is dedicated to enhancing drug formulation technology, ensuring effective patient solutions on a global scale. Their roster of innovative treatments underlines their commitment to tackling pressing healthcare challenges. The recent collaboration with Abera further solidifies Orexo's position in the sphere of cutting-edge pharmaceutical innovations.
Abera Bioscience AB focuses on developing groundbreaking vaccines based on proprietary platforms. Founded in 2012 and derived from reputable research institutions, Abera's work in nasal vaccine administration aims to ensure rapid responses to evolving health threats. Their lead candidate is already gearing up for clinical trials, signaling a proactive approach to vaccine development.
Frequently Asked Questions
What is the main goal of the Orexo and Abera collaboration?
The primary goal is to develop nasal powder vaccines utilizing Orexo's AmorphOX technology, starting with an intranasal influenza vaccine candidate.
How does AmorphOX technology enhance vaccine stability?
AmorphOX provides a stable powdered form of vaccines, improving their storage and transport capabilities, leading to enhanced patient accessibility.
What expertise does Abera bring to the partnership?
Abera has extensive experience in mucosal vaccine development, including a strong focus on innovative vaccine platforms and rapid production capabilities.
Why is an intranasal influenza vaccine significant?
Intranasal vaccines offer a convenient and effective method of administration, potentially reducing the spread of influenza and improving pandemic preparedness.
How is this collaboration funded?
The collaboration is predominantly funded through grants received by Abera, which support development in vaccine technology and readiness for health crises.
